Breaking News

Tweet TWEET

John Norris, JD, MBA Appointed CEO of Health Discovery Corporation

  John Norris, JD, MBA Appointed CEO of Health Discovery Corporation

Business Wire

SAVANNAH, Ga. -- December 27, 2012

Health Discovery Corporation (OTCBB: HDVY) announced today that on December
18, 2012, the Board of Directors appointed Dr. John Norris as its new CEO. He
succeeds Dr. Stephen Barnhill, who founded HDC, served as Chairman and CEO for
9 years and brought the Company to profitability in Q3 2012.

Dr. Norris, 65, until his appointment as CEO, was Executive Vice President,
Chief Technology Officer, and Chief Regulatory Officer of Health Discovery
Corporation and had served in that capacity for the past three years.

“I look forward to assuming the role of CEO at Health Discovery Corporation
and leading the Company to its next level of success,” stated John A. Norris,
JD, MBA, Chief Executive Officer of Health Discovery Corporation, “and I want
to personally thank Dr. Stephen Barnhill for his many years of dedication to
and leadership of HDC as Chairman and CEO from its inception through its
profitability. I also want to acknowledge his contribution as an inventor of
some 40 of HDC’s patents which are valuable assets of the Company. I look
forward to receiving his guidance and advice as I transition into my role as
CEO.”

Dr. Norris is a Former Principal Deputy Commissioner (second-in-command) and
Chief Operating Officer (COO) of the US FDA (Food and Drug Administration),
where with Former FDA Commissioner, Dr. Frank Young, he co-led the last major
reform of the FDA. This work was performed under the overall leadership of
President Ronald Reagan, HHS Secretaries Margaret Heckler and Dr. Otis Bowen,
FDA Commissioner Dr. Frank Young, Senator Orrin Hatch, and Congressman Paul
Rogers.

Dr. Norris is a Former Director and Co-Leader of the turnaround of Summit
Technology (NASDAQ: BEAM), inventor of computer-driven (semi-automated) laser
eye surgery. The FDA approved Summit’s version of LASIK using the Summit Apex
Plus Excimer Laser Workstation. Alcon Laboratories Inc. (NYSE: ACL), the
eye-products unit of Nestle, S.A., acquired Summit Technology, Inc., for $893
million. Summit Technology, based in Waltham, Massachusetts, had sales of $111
million.

In addition, Dr. Norris is a Former Corporate Officer, Corporate Executive
Vice President, and Worldwide Managing Director for Life Sciences Coaching and
Consulting at Hill & Knowlton. With 83 offices in 46 countries, Hill and
Knowlton is one of the world's largest marketing and management coaching and
consulting firms. It represents many of the world's premier healthcare, life
sciences, and healthcare-IT companies

Dr. Norris is a Director of Ischemix, a developer of next generation heart
medicines for advancing ischemia-reperfusion therapy. In addition, he was CEO
and is now Chairman of Needlebot, a developer and manufacturer of a next
generation software search engine for searching and analyzing “unstructured
text” contained in many sources, including nurses' notes, doctors' notes,
medical records, medical literature, and clinical trial records, at both the
Internet and Enterprise levels, as well as CEO and now Chairman of Norris
Capital, a corporate finance and holding company and a boutique legal,
regulatory, financial, marketing, and management/strategy coaching and
consulting firm. He is also a Director of Last Call Ventures, LLC, a
food-supplement company.

Dr. Norris was CEO and is now Chairman of FDDH (Food, Drug, Device, and
Healthcare), a healthcare-delivery and healthcare-IT coaching firm, and was
CEO and is now Chairman of the Joseph D. Norris, Esq., Health Law and Public
Policy Fund. The Joseph D. Norris, Esq., Health Law and Public Policy Fund
supports university scholarships for health law and public policy student
training.

Dr. Norris is also the Founder and Former Faculty-Editor-in-Chief and CEO of
the academic journal, The American Journal of Law and Medicine, which he
founded at Harvard, MIT, and Boston University, and which is now housed at
Boston University.

Dr. Norris is the Former Chairman of Global MedChoices, which is developing a
planned response to US healthcare reform at the convergence of three elements:
(1) advanced healthcare-IT, (2) specialty surgical services, and (3) key
medical tourism locations.

He is also a Former Chairman of the American Society of Law, Medicine, and
Ethics, a Former Vice-Chairman of the Massachusetts 4-H Foundation, and a
Former Vice-Chairman of the American Bar Association’s (ABA) Health Law
Committee.

Dr. Norris has been a consultant to the senior management of global companies,
including: Pfizer, Merck, J&J, and Glaxo.

Dr. Norris received a BA in Economics, with minors in Political Science and
Chemical Engineering, from the University of Rochester (where he was a two
varsity-sport athlete, and became a member of the university’s Trustee’s
Council); a JD with emphasis in health law, corporate law, and international
law from Cornell University’s Law School, where he was Editor-in-Chief of The
International Law Journal; an MBA with emphasis in healthcare and
healthcare-IT policy and management, from Cornell University’s S.C. Johnson
Graduate School of Management; and a Graduate Certificate from Harvard
University’s Kennedy School of Government. He is also a Former Harvard faculty
member, where he taught health policy and management, including healthcare-IT
reform, healthcare-delivery-system reform, and FDA reform.

According to HDC Board Chairman, Dr. Joe McKenzie, “John has served with
distinction for the past three years, and we intend to rely on his global
vision of the future of healthcare-delivery-system reform, of healthcare-IT
reform, and of FDA reform to drive the transformation of HDC into its next
phase of growth.”

HDC Director, Dr. Herb Fritsche stated, “I have known John for a long time and
have worked closely with him over the past three years. I can attest to his
impeccable personal integrity, intellectual honesty, outstanding vision, and
keen knowledge, insights, and judgment regarding the future of advanced
healthcare technology, healthcare-delivery-system reform, healthcare-IT
reform, and FDA reform. His strong business reputation, and his exceptional
advisory and executive capabilities, are all well known to me.”

HDC Director, Mr. Sumio Takeichi commented, “I have worked closely with John
for nearly 20 years, both on boards and in business ventures, and I, too, can
attest to his honesty, integrity, courage, insight, and intelligence when
under pressure. He has the best values, capabilities, and experiences of
anyone I know, for teasing potential out of HDC’s technologies and turning the
Company’s fortunes in a strongly positive direction. His availability and his
willingness to take on that challenge are both God sends.”

Dr. Stephen Barnhill, outgoing CEO, stated, “I have worked closely with John
off and on over the past 20 years and I admire John for his keen vision, his
prior successes, his comprehensive understanding of HDC’s technology and his
business insights and contacts. He is the perfect choice to succeed me, and I
am absolutely committed to assisting him with a smooth transition and
supporting him in any way that I can to bring success to HDC and its
shareholders.”

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses
advanced mathematical techniques to analyze large amounts of data to uncover
patterns that might otherwise be undetectable. It operates primarily in the
emerging field of personalized medicine where such tools are critical to
scientific discovery. Its primary business consists of licensing its
intellectual property and developing its own product line of biomarker-based
diagnostic tests that include human genes and genetic variations, as well as
gene, protein, and metabolic expression differences and image analysis in
digital pathology and radiology. For more information, see
www.healthdiscoverycorp.com.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, the accuracy of which is
necessarily subject to risks and uncertainties, including, without limitation,
statements regarding future performance, opportunities and investments, and
anticipated results in general. From time to time the Company may make other
forward-looking statements relating to other matters, including without
limitation, commercialization plans and strategic partnerships. Actual results
may differ materially due to a variety of factors, including, among other
things, the acceptance of our approach to applying mathematics computer
science and physics into the disciplines of biology, organic chemistry and
medicine and our products and technologies associated with those approaches,
the ability to develop or commercialize new drugs, therapies or other products
based on our approaches, and other factors set forth from time to time in the
Company’s Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this
document are made as of the date hereof based on information available to the
Company as of the date hereof, and the Company assumes no obligation to update
any forward-looking statement or cautionary statement.

Contact:

Health Discovery Corporation
Brandyn Reagan, 912-443-1987
breagan@healthdiscoverycorp.com
 
Press spacebar to pause and continue. Press esc to stop.